IL288950B2 - History of pyridine-3-yl - Google Patents
History of pyridine-3-ylInfo
- Publication number
- IL288950B2 IL288950B2 IL288950A IL28895021A IL288950B2 IL 288950 B2 IL288950 B2 IL 288950B2 IL 288950 A IL288950 A IL 288950A IL 28895021 A IL28895021 A IL 28895021A IL 288950 B2 IL288950 B2 IL 288950B2
- Authority
- IL
- Israel
- Prior art keywords
- model
- technical unit
- attack
- test
- computer system
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Debugging And Monitoring (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2019065963 | 2019-06-18 | ||
| PCT/EP2020/066767 WO2020254408A1 (en) | 2019-06-18 | 2020-06-17 | Pyridin-3-yl derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL288950A IL288950A (en) | 2022-02-01 |
| IL288950B1 IL288950B1 (en) | 2024-11-01 |
| IL288950B2 true IL288950B2 (en) | 2025-03-01 |
Family
ID=71105482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL288950A IL288950B2 (en) | 2019-06-18 | 2020-06-17 | History of pyridine-3-yl |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US12479820B2 (https=) |
| EP (1) | EP3986884A1 (https=) |
| JP (1) | JP7494222B2 (https=) |
| KR (1) | KR102786045B1 (https=) |
| CN (1) | CN114026082B (https=) |
| AR (1) | AR119162A1 (https=) |
| AU (1) | AU2020298014B2 (https=) |
| BR (1) | BR112021025236A2 (https=) |
| CA (1) | CA3143618A1 (https=) |
| CL (1) | CL2021003348A1 (https=) |
| IL (1) | IL288950B2 (https=) |
| MA (1) | MA56504A (https=) |
| MX (1) | MX2021015727A (https=) |
| PH (1) | PH12021553178A1 (https=) |
| SG (1) | SG11202111162PA (https=) |
| TW (1) | TWI845708B (https=) |
| UA (1) | UA130692C2 (https=) |
| WO (1) | WO2020254408A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3802517T (pt) | 2018-06-07 | 2023-03-20 | Idorsia Pharmaceuticals Ltd | Derivados de piridinilo substituídos por alcoxi como antagonistas do recetor de lpa1 e a sua utilização no tratamento da fibrose |
| JP7665619B2 (ja) | 2019-12-04 | 2025-04-21 | イドルシア・ファーマシューティカルズ・リミテッド | 線維性疾患の治療に使用するためのアゼチジンｌｐａ１受容体アンタゴニストのピルフェニドン及び／又はニンテダニブとの合剤 |
| WO2025169931A1 (ja) * | 2024-02-05 | 2025-08-14 | Ｕｂｅ株式会社 | カルボキサミド化合物 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL130088C (https=) | 1960-03-14 | |||
| WO1994006802A1 (fr) * | 1992-09-18 | 1994-03-31 | Yoshitomi Pharmaceutical Industries, Ltd. | Compose de thienodiazepine et son utilisation medicinale |
| GB9420763D0 (en) | 1994-10-14 | 1994-11-30 | Glaxo Inc | Acetamide derivatives |
| GB9919776D0 (en) | 1998-08-31 | 1999-10-27 | Zeneca Ltd | Compoujnds |
| AU7961300A (en) | 1999-10-29 | 2001-05-14 | Yamanouchi Pharmaceutical Co., Ltd. | Kainic acid neurocytotoxicity inhibitors |
| AU2001262185A1 (en) | 2000-04-10 | 2001-10-23 | Novartis Ag | Substituted (hetero)aryl carboxamide derivatives as microsomal triglyceride transfer protein (mtp) and apolipoprotein b (apo b) secretion |
| WO2002062389A1 (en) | 2001-02-08 | 2002-08-15 | Ono Pharmaceutical Co., Ltd. | Remedies for urinary diseases comprising lpa receptor controlling agents |
| US7435824B2 (en) | 2002-04-19 | 2008-10-14 | Bristol-Myers Squibb Company | Prodrugs of potassium channel inhibitors |
| TW200403058A (en) | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
| TW200505902A (en) | 2003-03-20 | 2005-02-16 | Schering Corp | Cannabinoid receptor ligands |
| WO2004110350A2 (en) | 2003-05-14 | 2004-12-23 | Torreypines Therapeutics, Inc. | Compouds and uses thereof in modulating amyloid beta |
| WO2005023761A2 (en) | 2003-09-11 | 2005-03-17 | Kemia, Inc. | Cytokine inhibitors |
| JPWO2005037269A1 (ja) | 2003-10-21 | 2006-12-28 | 住友製薬株式会社 | 新規ピペリジン誘導体 |
| EP1684759A4 (en) | 2003-11-12 | 2009-06-10 | Merck & Co Inc | 4-phenyl-piperidinosulfonyl-Glycine-TRANSPORTER INHIBITORS |
| EP1687296A1 (en) | 2003-11-18 | 2006-08-09 | Warner-Lambert Company LLC | Antibacterial aminoquinazolidinedione derivatives |
| WO2006091862A2 (en) | 2005-02-24 | 2006-08-31 | Kemia, Inc. | Cytokine inhibitors and their use in therapy |
| CN101198590B (zh) | 2005-08-24 | 2012-05-09 | 卫材R&D管理有限公司 | 吡啶衍生物及嘧啶衍生物（3） |
| WO2007058990A2 (en) | 2005-11-14 | 2007-05-24 | Kemia, Inc. | Therapy using cytokine inhibitors |
| CA2691214A1 (en) | 2006-06-09 | 2007-12-21 | Kemia, Inc. | Therapy using cytokine inhibitors |
| JP5164510B2 (ja) | 2006-10-06 | 2013-03-21 | 日本曹達株式会社 | 含窒素複素環化合物および有害生物防除剤 |
| WO2008115281A2 (en) | 2006-10-16 | 2008-09-25 | Myriad Genetics, Inc. | Compounds for treating viral infections |
| EP2212322B1 (en) | 2007-10-18 | 2012-04-04 | Merck Sharp & Dohme Corp. | Quinolizidinone m1 receptor positive allosteric modulators |
| AU2009239500B2 (en) | 2008-04-21 | 2014-01-30 | Lexicon Pharmaceuticals, Inc. | LIMK2 inhibitors, compositions comprising them, and methods of their use |
| PT2303270T (pt) | 2008-05-05 | 2017-08-25 | Sanofi Sa | Derivados fundidos do ácido ciclopentanocarboxílico substituídos por acilamino e sua utilização como produtos farmacêuticos |
| UY32072A (es) | 2008-08-26 | 2010-03-26 | Boehringer Ingelheim Int | Tienopirimidinas para composiciones farmacéuticas |
| KR101678255B1 (ko) * | 2009-09-25 | 2016-11-21 | 아스텔라스세이야쿠 가부시키가이샤 | 치환 아미드 화합물 |
| ES2682303T3 (es) | 2010-08-05 | 2018-09-19 | Zoetis Services Llc | Derivados de isoxazolina como agentes antiparasitarios |
| TW201305178A (zh) | 2010-10-29 | 2013-02-01 | Glenmark Pharmaceuticals Sa | 作為ｍＰＧＥＳ－１抑制物的三環化合物 |
| DK2648726T3 (da) | 2010-12-07 | 2018-07-16 | Amira Pharmaceuticals Inc | Polycyklisk lpa1-antagonist og anvendelser deraf |
| JP6097998B2 (ja) | 2010-12-16 | 2017-03-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ロイコトリエン生成のビアリールアミドインヒビター |
| PH12013501831B1 (en) | 2011-03-10 | 2019-06-14 | Zoetis Services Llc | Spirocyclic isoxazoline derivatives as antiparasitic agents |
| CA2859965A1 (en) | 2011-12-21 | 2013-06-27 | Ardelyx, Inc. | Non-systemic tgr5 agonists |
| WO2014079805A1 (en) | 2012-11-23 | 2014-05-30 | Boehringer Ingelheim International Gmbh | Pyrazole compounds for treating hairloss |
| EP2970200A1 (en) * | 2013-03-13 | 2016-01-20 | Abbvie Inc. | Pyridine cdk9 kinase inhibitors |
| ES2693718T3 (es) | 2013-11-06 | 2018-12-13 | Bristol-Myers Squibb Company | Derivados de piridina sustituidos útiles como inhibidores de GSK-3 |
| AR108185A1 (es) | 2016-04-06 | 2018-07-25 | Abbvie Inc | Amidas terciarias y método para su uso |
| PT3802517T (pt) | 2018-06-07 | 2023-03-20 | Idorsia Pharmaceuticals Ltd | Derivados de piridinilo substituídos por alcoxi como antagonistas do recetor de lpa1 e a sua utilização no tratamento da fibrose |
| JP7665619B2 (ja) | 2019-12-04 | 2025-04-21 | イドルシア・ファーマシューティカルズ・リミテッド | 線維性疾患の治療に使用するためのアゼチジンｌｐａ１受容体アンタゴニストのピルフェニドン及び／又はニンテダニブとの合剤 |
-
2020
- 2020-06-16 AR ARP200101686A patent/AR119162A1/es unknown
- 2020-06-17 WO PCT/EP2020/066767 patent/WO2020254408A1/en not_active Ceased
- 2020-06-17 SG SG11202111162PA patent/SG11202111162PA/en unknown
- 2020-06-17 AU AU2020298014A patent/AU2020298014B2/en active Active
- 2020-06-17 EP EP20733601.7A patent/EP3986884A1/en active Pending
- 2020-06-17 PH PH1/2021/553178A patent/PH12021553178A1/en unknown
- 2020-06-17 UA UAA202107611A patent/UA130692C2/uk unknown
- 2020-06-17 MA MA056504A patent/MA56504A/fr unknown
- 2020-06-17 TW TW109120315A patent/TWI845708B/zh active
- 2020-06-17 KR KR1020227001133A patent/KR102786045B1/ko active Active
- 2020-06-17 JP JP2021574814A patent/JP7494222B2/ja active Active
- 2020-06-17 US US17/620,520 patent/US12479820B2/en active Active
- 2020-06-17 CA CA3143618A patent/CA3143618A1/en active Pending
- 2020-06-17 IL IL288950A patent/IL288950B2/en unknown
- 2020-06-17 MX MX2021015727A patent/MX2021015727A/es unknown
- 2020-06-17 BR BR112021025236A patent/BR112021025236A2/pt unknown
- 2020-06-17 CN CN202080044333.8A patent/CN114026082B/zh active Active
-
2021
- 2021-12-15 CL CL2021003348A patent/CL2021003348A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020254408A1 (en) | 2020-12-24 |
| CN114026082B (zh) | 2024-06-07 |
| CA3143618A1 (en) | 2020-12-24 |
| IL288950B1 (en) | 2024-11-01 |
| CN114026082A (zh) | 2022-02-08 |
| AR119162A1 (es) | 2021-12-01 |
| KR20220020921A (ko) | 2022-02-21 |
| TWI845708B (zh) | 2024-06-21 |
| MX2021015727A (es) | 2022-01-24 |
| CL2021003348A1 (es) | 2022-09-23 |
| KR102786045B1 (ko) | 2025-03-24 |
| UA130692C2 (uk) | 2026-04-22 |
| PH12021553178A1 (en) | 2022-11-07 |
| JP7494222B2 (ja) | 2024-06-03 |
| IL288950A (en) | 2022-02-01 |
| MA56504A (fr) | 2022-04-27 |
| BR112021025236A2 (pt) | 2022-02-01 |
| EP3986884A1 (en) | 2022-04-27 |
| US20220251068A1 (en) | 2022-08-11 |
| JP2022537177A (ja) | 2022-08-24 |
| AU2020298014A1 (en) | 2022-02-10 |
| US12479820B2 (en) | 2025-11-25 |
| AU2020298014B2 (en) | 2026-02-05 |
| SG11202111162PA (en) | 2021-11-29 |
| TW202115011A (zh) | 2021-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12386969B2 (en) | Method for checking the security of a technical unit | |
| US8413237B2 (en) | Methods of simulating vulnerability | |
| US20220171697A1 (en) | Fuzzy testing a software system | |
| Moukahal et al. | Vulnerability-oriented fuzz testing for connected autonomous vehicle systems | |
| EP4276630A1 (en) | Fuzzy testing a software system | |
| IL288950B2 (en) | History of pyridine-3-yl | |
| US20130031532A1 (en) | Method, computer, and device for validating execution of tasks in adaptable computer systems | |
| CN120811778A (zh) | 一种基于虚拟攻防推演的电力网络漏洞分析系统及方法 | |
| KR20240126308A (ko) | 차량 내부 네트워크의 보안을 평가하기 위한 방법 | |
| Moradi et al. | Machine learning-assisted fault injection | |
| CN120705875A (zh) | 基于ai与区块链的智能合约自动优化与风险预警方法及系统 | |
| Marksteiner et al. | A model-driven methodology for automotive cybersecurity test case generation | |
| Marksteiner et al. | Approaches for automating cybersecurity testing of connected vehicles | |
| Loper | The modeling and simulation life cycle process | |
| US20240428128A1 (en) | Computing system for implementing system model using big data machine learning | |
| US12468870B2 (en) | Method and system for carrying out a simulation | |
| US20220382865A1 (en) | Persistent security configuration monitoring | |
| Bouquet et al. | Model-based testing for functional and security test generation | |
| Soni | AI-Enabled Simulation-Based SIL Setup For Motor Controllers: Enhancing Software Testing Efficiency | |
| CN117290848A (zh) | 基于ai分析的软件组件稳定性测试方法及大数据服务系统 | |
| EP4401016A1 (en) | Method for generating and training a system model, selecting a controller, system, computer-system | |
| CN119094198B (zh) | 一种基于TTPs脚本的攻击链数据自动生成采集方法 | |
| CN115834187B (zh) | 车辆控制器漏洞管理方法、系统、电子设备、存储介质 | |
| EP4400975A1 (en) | Method for training a system model, selecting a controller, system, computer-system | |
| EP4711934A1 (en) | Operational design driven testing of and manufacturing an electronic control unit |